These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 31278574)

  • 1. Temporal validation of metabolic nodal response of esophageal cancer to neoadjuvant chemotherapy as an independent predictor of unresectable disease, survival, and recurrence.
    Findlay JM; Dickson E; Fiorani C; Bradley KM; Mukherjee S; Gillies RS; Maynard ND; Middleton MR
    Eur Radiol; 2019 Dec; 29(12):6717-6727. PubMed ID: 31278574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting Pathologic Response of Esophageal Cancer to Neoadjuvant Chemotherapy: The Implications of Metabolic Nodal Response for Personalized Therapy.
    Findlay JM; Bradley KM; Wang LM; Franklin JM; Teoh EJ; Gleeson FV; Maynard ND; Gillies RS; Middleton MR
    J Nucl Med; 2017 Feb; 58(2):266-275. PubMed ID: 27635027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic nodal response as a prognostic marker after neoadjuvant therapy for oesophageal cancer.
    Findlay JM; Bradley KM; Wang LM; Franklin JM; Teoh EJ; Gleeson FV; Maynard ND; Gillies RS; Middleton MR
    Br J Surg; 2017 Mar; 104(4):408-417. PubMed ID: 28093719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Restaging oesophageal cancer after neoadjuvant therapy with (18)F-FDG PET-CT: identifying interval metastases and predicting incurable disease at surgery.
    Findlay JM; Gillies RS; Franklin JM; Teoh EJ; Jones GE; di Carlo S; Gleeson FV; Maynard ND; Bradley KM; Middleton MR
    Eur Radiol; 2016 Oct; 26(10):3519-33. PubMed ID: 26883329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic tumour and nodal response to neoadjuvant chemotherapy on FDG PET-CT as a predictor of pathological response and survival in patients with oesophageal adenocarcinoma.
    Moore JL; Subesinghe M; Santaolalla A; Green M; Deere H; Van Hemelrijck M; Lagergren J; Chicklore S; Maisey N; Gossage JA; Kelly M; Baker CR; Davies AR;
    Eur Radiol; 2023 May; 33(5):3647-3659. PubMed ID: 36920518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Routinely staging gastric cancer with
    Findlay JM; Antonowicz S; Segaran A; El Kafsi J; Zhang A; Bradley KM; Gillies RS; Maynard ND; Middleton MR
    Eur Radiol; 2019 May; 29(5):2490-2498. PubMed ID: 30643947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Significance of (18)F-fluorodeoxyglucose Positron Emission Tomography (FDG-PET)-Positive Lymph Nodes Following Neoadjuvant Chemotherapy and Surgery for Resectable Thoracic Esophageal Squamous Cell Carcinoma.
    Yasuda T; Yano M; Miyata H; Yamasaki M; Takiguchi S; Fujiwara Y; Doki Y
    Ann Surg Oncol; 2015 Aug; 22(8):2599-607. PubMed ID: 25524011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nodal FDG-PET/CT uptake influences outcome and relapse location among esophageal cancer patients submitted to chemotherapy or radiochemotherapy.
    Jimenez-Jimenez E; Mateos P; Ortiz I; Aymar N; Roncero R; Gimenez M; Pardo J; Sabater S
    Clin Transl Oncol; 2019 Sep; 21(9):1159-1167. PubMed ID: 30661172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significance of baseline FDG-PET/CT scan as a method of staging regional lymph nodes in patients with operable distal oesophageal or gastroesophageal junction adenocarcinoma.
    Papaxoinis G; Weaver JMJ; Khoja L; Patrao A; Stamatopoulou S; Alchawaf A; Owen-Holt V; Germetaki T; Kordatou Z; Mansoor W
    Acta Oncol; 2017 Sep; 56(9):1224-1232. PubMed ID: 28524708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of lymph node to primary tumor standardized uptake value ratio in unresectable esophageal cancer.
    Chen PJ; Yap WK; Chang YC; Tseng CK; Chao YK; Hsieh JC; Pai PC; Lee CH; Yang CK; Ho AT; Hung TM
    BMC Cancer; 2020 Jun; 20(1):545. PubMed ID: 32522275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive value of nodal maximum standardized uptake value of pretreatment [18F]fluorodeoxyglucose positron emission tomography imaging in patients with esophageal cancer.
    Yap WK; Chang YC; Tseng CK; Hsieh CH; Chao YK; Su PJ; Hou MM; Yang CK; Pai PC; Lin CR; Hsieh CE; Wu YY; Hung TM
    Dis Esophagus; 2017 Aug; 30(8):1-10. PubMed ID: 28575243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagus.
    Noble F; Nolan L; Bateman AC; Byrne JP; Kelly JJ; Bailey IS; Sharland DM; Rees CN; Iveson TJ; Underwood TJ; Bateman AR
    World J Gastroenterol; 2013 Dec; 19(48):9282-93. PubMed ID: 24409055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 18F-FDG PET in patients with esophageal squamous cell carcinoma undergoing curative surgery: prognostic implications.
    Choi JY; Jang HJ; Shim YM; Kim K; Lee KS; Lee KH; Choi Y; Choe YS; Kim BT
    J Nucl Med; 2004 Nov; 45(11):1843-50. PubMed ID: 15534053
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    van der Aa DC; Gisbertz SS; Anderegg MCJ; Lagarde SM; Klaassen R; Meijer SL; van Dieren S; Hulshof M; Bergman J; Bennink RJ; van Laarhoven HWM; van Berge Henegouwen MI
    J Gastrointest Cancer; 2024 Mar; 55(1):270-280. PubMed ID: 37393217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Locally advanced esophageal adenocarcinoma: response to neoadjuvant chemotherapy and survival predicted by ([18F])FDG-PET/CT.
    Kauppi JT; Oksala N; Salo JA; Helin H; Karhumäki L; Kemppainen J; Sihvo EI; Räsänen JV
    Acta Oncol; 2012 May; 51(5):636-44. PubMed ID: 22208782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complete Metabolic Response on Interim
    Chen S; Ibrahim NK; Yan Y; Wong ST; Wang H; Wong FC
    Oncologist; 2017 May; 22(5):526-534. PubMed ID: 28377466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complete pathological response (pCR) in gastroesophageal cancer: Correlation with metabolic response.
    Cabral F; Cruz A; Casaca R; Monteiro C; Ramos P; Pedro C; Brandão F; Fonseca R; Ratão P; Salgado L; Pinto I; Abecasis N
    Cancer Radiother; 2020 Dec; 24(8):834-841. PubMed ID: 33191120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of positron emission tomography-computed tomography in predicting survival after neoadjuvant chemotherapy and surgery for oesophageal adenocarcinoma.
    Gillies RS; Middleton MR; Han C; Marshall RE; Maynard ND; Bradley KM; Gleeson FV
    Br J Surg; 2012 Feb; 99(2):239-45. PubMed ID: 22329010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of dynamic contrast-enhanced MRI and
    Withey SJ; Owczarczyk K; Grzeda MT; Yip C; Deere H; Green M; Maisey N; Davies AR; Cook GJ; Goh V;
    Eur J Surg Oncol; 2023 Oct; 49(10):106934. PubMed ID: 37183047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relevance of [18F]fluorodeoxyglucose positron emission tomography-positive lymph nodes after neoadjuvant chemotherapy for squamous cell oesophageal cancer.
    Miyata H; Yamasaki M; Takahashi T; Murakami K; Kurokawa Y; Nakajima K; Takiguchi S; Mori M; Doki Y
    Br J Surg; 2013 Oct; 100(11):1490-7. PubMed ID: 24037571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.